About Us
Overview
SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), is dedicated to the development and commercialization of non-opioid pain management products. We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.
The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a marketed prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain. ZTlido® possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period. Click here for ZTLido’s Important Safety Information and US Prescribing Information.
We have acquired two FDA approved non-opioid pain products, GLOPERBA and ELYXYB®, for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults. We launched ELYXYB® in the U.S. in April 2023 and are planning to commercialize GLOPERBA in 2024.
Our three product candidates are (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXATM”), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica and has received Fast Track Status from the FDA. Currently there is no FDA approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain (“LBP”) and has received Fast Track Status from the FDA; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia. If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in the United States.
SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them the most.
Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company.
Leadership
The mission of the Leadership Team is to bolster our proprietary pain management clinical pipeline and technology by employing years of expertise that come with overseeing market access, commercialization, clinical development, manufacturing, CMC, corporate and business development, and regulatory affairs programs. These seasoned professionals bring SCILEX a type of leadership that is unmatched in the pharmaceutical industry.
Board of Directors
Our Culture
We’re not just your average pharmaceutical company. We’re a different breed altogether. Ours is a passionate team of talented people working together to make a difference in the world of pain management. Our team-spirited approach ensures a collaborative, engaged, and focused atmosphere where we push thinking further, fostering innovation and fervently pursuing viable solutions for patients and providers through groundbreaking technologies.
We believe in the “law of science” and that we’re all entitled to live healthy and pain-free lives—because we’re patients, too. We don’t just seek answers. We seek THE answer.
Mission
Our mission is to advance non-opioid therapeutic options to treat acute and chronic pain in patients with greatest unmet needs. SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them most.
Vision
We are uncompromising in our focus to become the global pharmaceutical leader in pain management through social, environmental, economic, and ethical principles.
Values
-
- Responsibility / Excellence
- Accountability / Diversity
- Integrity / Quality